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ABSTRACT 
 
Background 
 Although people who use drugs (PWUD) are a key population recommended to 
receive pre-exposure prophylaxis (PrEP) to prevent HIV, few data are available to guide 
PrEP delivery in this underserved group. We therefore examined the willingness to 
initiate PrEP, the anticipation of HIV risk reduction while on PrEP, and the acceptability 
of PrEP based on a number of known PrEP attributes among high-risk PWUD.  
 
Methods 
 In a cross-sectional study of 400 HIV-negative, opioid dependent individuals 
enrolled in a methadone program and reporting recent risk behaviors, we examined 
independent correlates of being willing to initiate PrEP. Participants also ranked the 
eight hypothetical PrEP program scenarios with varied combinations of six attributes 
related to PrEP (cost, dosing, efficacy, side-effects, treatment setting, and frequency of 
HIV testing). 
 
Results 
 While only 72 (18%) were aware of PrEP, after being given a description of it, 
251 (62.7%) were willing to initiate PrEP. Willingness to initiate PrEP was associated 
with having neurocognitive impairment (aOR=3.184, p=0.004) and higher perceived HIV 
risk (aOR=8.044, p<0.001). Among those willing to initiate PrEP, only 12.5% and 
28.2%, respectively, indicated that they would always use condoms and not share 
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injection equipment while on PrEP. PrEP acceptability ranged from 30.6% to 86.3% with 
a mean acceptability of 56.2% across the eight hypothetical PrEP program scenarios. 
The PrEP program scenario with the highest acceptability had the following attribute 
levels: insurance covered, daily dosing, 95% effective, no side-effects, treatment at HIV 
clinic, and HIV testing needed every six months.  
 
Conclusions 
Our findings showed high acceptability of PrEP in response to different PrEP 
program scenarios with different attribute profiles. While willingness to initiate PrEP was 
high and correlated with being at elevated risk for HIV and having NCI, anticipated 
higher risk behaviors in this group even while on PrEP suggests that the next 
generation of HIV prevention approaches may need to combine biomedical and 
behavioral components to improve adherence to PrEP and to sustain HIV risk reduction 
over time.
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INTRODUCTION 
 
Background 
HIV (Human Immunodeficiency Virus) continues to be a major global public 
health issue. Since the start of the epidemic, more than 70 million people have become 
infected with HIV globally and 35 million have died of AIDS-related illnesses. In 2016 
alone, approximately 36.7 million people were living with HIV (PLWH), including 1.8 
million children, with a global HIV prevalence of 0.8% among adults aged 15-49 years. 
The same year, there were roughly 1.8 million new HIV infections – a decline from 2.1 
million new infections in 2015, and about 1 million deaths from HIV-related illnesses 
were reported in the same year (UNAIDS, 2017). The burden of the epidemic continues 
to vary considerably between countries and regions, with the vast majority of PLWH 
located in low- and middle- income countries.  
HIV remains a persistent problem for the United States as well. The Centers for 
Disease Control and Prevention (CDC) estimated that a 1.1 million people in the United 
States were living with HIV at the end of 2014. Nearly one in seven of those are 
unaware of their HIV sero-status. In 2014, there were an estimated 37,600 new HIV 
infections, which represents a decline of 10% from 2010 (CDC, 2016b). The size of the 
epidemic is relatively small compared to the country’s population, but is heavily 
concentrated among several key affected populations. Most new HIV infections occur 
among men who have sex with men (MSM), with African American/black men who have 
sex with men most affected. African American/black heterosexual women are also 
disproportionately affected (CDC, 2016b). 
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According to the recent CDC estimates, of the 1.1 million PLWH in the United 
States in 2014, an estimated 85% were diagnosed. This means that 15% 
(approximately 1 in 6 PLWH) were unaware of their infection and therefore not 
considering the care and treatment they need to stay healthy. Of those PLWH, 62% 
received HIV-related care, 48% 
were retained in care, and 49% 
had achieved viral suppression. In 
other words, approximately 3 out 
of 5 PLWH had the virus under 
control (CDC, 2016c). The CDC 
further estimated that 9 out of 10 
HIV infections were transmitted by 
people who are not diagnosed or 
not in care. Reducing the number 
of undiagnosed HIV infections and 
getting more people into care 
present the greatest opportunities to improve viral suppression in America. This 
underscores the importance of continued and intensified efforts to reach more people 
with testing and to make sure that those with the HIV receive prompt, ongoing care and 
treatment to help them live longer, healthier lives and prevent the spread of HIV to 
others. 
From the outset of the HIV epidemic, the use of substance, including alcohol use, 
injection drug use (IDU), and non-IDU, has been closely associated for its potential 
 
Figure 1: HIV continuum of care, U.S., 2014 (CDC, 2016c) 
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influence on HIV disease progression (Degenhardt et al., 2013). Despite the recent 
decline in the proportion of HIV infections attributed to people who use drugs (PWUD) 
(CDC, 2016b), they still remain a priority population because of the potential for an 
increase in HIV transmission as a result of preventable drug-related (e.g., needle 
sharing) and sex-related (e.g., inconsistent condom use) risk behaviors (Alipour, 
Haghdoost, Sajadi, & Zolala, 2013; Marshall et al., 2014; Nadol et al., 2016; Strathdee 
et al., 2010; Volkow & Montaner, 2011). Failing to effectively intervene with PWUD has 
resulted in poor individual outcomes, and also threatens public health by increasing the 
likelihood of HIV transmission via PWUD. These high-risk individuals – and the 
communities in which they live – would greatly benefit from improving and expanding 
existing EBIs, and introducing new approaches to HIV prevention. 
HIV oral pre-exposure prophylaxis (PrEP), which involves routine self-
administration of antiretroviral medication, TruvadaTM (Tenofovir/emtricitabine), 
represents a significant innovation in our public health response to reduce the HIV 
epidemic. Large-scale clinical trials have proven daily PrEP to be safe, well-tolerated, 
and efficacious for reducing HIV infection among those who are at substantial risk of 
acquiring HIV infection, such as men who have sex with men (MSM), people who inject 
drugs (PWID), sex workers, and transgender people (Baeten  et al., 2012; Choopanya 
et al., 2013; Grant et al., 2010; Thigpen  et al., 2012; Van Damme  et al., 2012). Based 
on this evidence, the World Health Organization (WHO) and the US Centers for Disease 
Control and Prevention (CDC) have recommended PrEP for individuals at substantial 
risk for HIV infection (CDC, 2014; WHO, 2015), and the US National HIV/AIDS Strategy 
through 2020 priorities have expanded access to comprehensive PrEP services among 
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those who are interested and may benefit (The White House Office of National AIDS 
Policy, 2015). 
Despite the unequivocal evidence and widespread PrEP availability in the US 
and its coverage by almost all insurance, its uptake among the most-at-risk populations, 
has been strikingly low (Kirby & Thornber-Dunwell, 2014), and non-existent among 
PWUD. The overall success of the PrEP strategy, which hinges heavily on PrEP uptake, 
involves a high level of user awareness, willingness to use it, and compliance (Peng et 
al., 2012). In recent years, there has been growth in studies examining attitudes, 
awareness, and willingness to use PrEP, especially among MSM, with limited research 
among high-risk PWUD (Ferrer et al., 2016; Goedel, Halkitis, Greene, & Duncan, 2016; 
Gredig, Uggowitzer, Hassler, Weber, & Nideröst, 2016; Hoagland et al., 2016; Holt et 
al., 2012; Kuo et al., 2016; Peng et al., 2012; Stein, Thurmond, & Bailey, 2014; Young, 
Li, & McDaid, 2013). Whether or not PWUD enrolled in substance abuse treatment 
would be willing to initiate PrEP, however, has not be explored. Furthermore, no prior 
studies have assessed individuals’ anticipated likelihood of engaging in safer drug use 
(i.e., not sharing of needles/works) and safer sex (i.e., consistent condom use) while on 
PrEP among PWUD within a drug treatment setting (e.g., methadone maintenance 
program: MMP) where high risk individuals are concentrated. 
PrEP programs developed based on stakeholders’ preferences may improve 
successful identification, engagement, and adherence of individuals at substantial risk 
for HIV infection in PrEP care, as highlighted in the PrEP cascade. In this context, few 
studies have assessed information about individuals’ attitudes and preferences of 
various attributes (e.g., cost, side-effects, dose, dispensing venue, etc.) of PrEP 
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programs. Those studies were, however, focused mostly among MSM (Eisingerich et 
al., 2012; Galea et al., 2011a; Wheelock et al., 2013), and no such studies have been 
conducted among PWUD within a drug treatment setting (e.g., methadone maintenance 
program: MMP) where high risk individuals are concentrated. As demonstration projects 
are beginning to develop, there is an urgent need to understand how high-risk PWUD 
value various aspects of PrEP programs.  
A variety of behavioral, clinical, service delivery, socio-cultural, and other 
structural challenges represent a significant challenge to PrEP implementation among 
this underserved population. Prior studies have primarily focused on other risk 
populations, including MSM and transgender individuals, and no studies have been 
conducted among PWUD within a MMP to assess patients’ willingness to use PrEP nor 
the influence of various attributes on PrEP program acceptability. A novel aspect of this 
thesis is that the results from this study will be the first to offer valuable insights that can 
help care providers implement PrEP more effectively among PWUD by focusing our 
efforts on the most critical aspects of PrEP treatment. Importantly, this study will provide 
preliminary evidence to inform the initiation of PrEP services and integration of 
additional strategies (e.g., behavioral interventions) within MMPs to optimize HIV 
prevention efforts. 
 
Research Objectives 
The overall objective of this study was to understand individuals’ awareness and 
willingness to use PrEP and to investigate preferences about the delivery of the PrEP 
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program among high-risk PWUD in treatment. Specifically, three research aims were 
proposed to facilitate achieving the overall objective of the study: 
• To assess awareness and willingness to use PrEP among high-risk PWUD in 
treatment. 
• To assess demographic and behavioral correlates of willingness to use PrEP 
among high-risk PWUD in treatment. 
• To investigate the acceptability of hypothetical PrEP programs and the impact of 
various PrEP attributes on PrEP program acceptability among high-risk PWUD in 
treatment. 
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LITERATURE REVIEW 
 
Available HIV Prevention Strategies 
Over the last three decades, research has led to a growing number of efficacious 
and cost-effective strategies to reduce the risk of HIV infection. Many of these 
approaches can be particularly effective when tailored to address the social, community, 
financial, and structural factors that place specific groups at risk. In the United States, 
proven strategies (CDC, 2016a) include: 
HIV testing and linkage to care: Testing is a critical component of prevention 
efforts because when people learn they are infected, research shows that they take 
steps to protect their own health and prevent HIV transmission to others. Linkage to 
care helps ensure PLWH receive life-saving medical care and treatment, and helps 
reduce their risk of transmitting HIV (Christopoulos et al., 2011). 
Antiretroviral therapy (ART): Treating PLWH early in their infection dramatically 
reduces the risk of transmitting the virus to others, underscoring the importance of HIV 
testing and access to medical care and treatment. Treatment as Prevention (TaP) has 
emerged as one of the ways for reducing the risk of transmission from HIV-infected 
pregnant women to their infants (Carpenter et al., 2000; WHO, 2012).Access to 
condoms and sterile syringes: In order for HIV prevention efforts to work, PWLH, or at 
risk for, HIV infection need to have access to effective prevention tools (CDC, 2016a). 
Substance abuse treatment: Effective substance abuse treatment that helps 
PWUD stop injecting eliminates the risk of HIV transmission through injection drug use 
(CDC, 2016a). 
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Screening and treatment for other sexually transmitted infections: Many 
sexually transmitted infections (STIs) increase an individual’s risk of acquiring and 
transmitting HIV, and STI treatment may reduce HIV viral load. Therefore, STI 
screening and treatment may reduce risk for HIV transmission (CDC, 2016a).  
In addition, pre-exposure prophylaxis, or PrEP, is a new prevention 
intervention in which HIV-uninfected people take a daily dose of antiretroviral 
medication to lower their chances of acquiring HIV (CDC, 2014; WHO, 2015). The 
efficacy of oral PrEP has been shown in recent randomized control trials and is highest 
when the drug is used as directed (Baeten  et al., 2012; Choopanya et al., 2013; Grant 
et al., 2010; Thigpen  et al., 2012; Van Damme  et al., 2012). 
 
Pre-Exposure Prophylaxis (PrEP) 
The recent advent of PrEP has provided unprecedented opportunities in our 
public health response to curtail the HIV epidemic. Findings from recent PrEP trials 
have demonstrated that daily PrEP dose can significantly reduce the risk of HIV 
transmission among those who are at substantial risk of acquiring HIV infection, such as 
MSM, people who inject drugs (PWID), sex workers, and transgender people (Baeten  
et al., 2012; Choopanya et al., 2013; Grant et al., 2010; Thigpen  et al., 2012; Van 
Damme  et al., 2012). Based on these findings, the CDC released clinical practice 
guidelines on the use of PrEP for HIV prevention, identifying high-risk PWUD as one of 
the key populations that could benefit from the use of PrEP (CDC, 2014). The 
guidelines also indicate that PrEP should be given as an additional prevention choice 
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for people who are at substantial risk of HIV infection as part of combination HIV 
prevention approaches. 
 
PrEP Guidelines 
On the basis of this evidence, the Centers for Disease Control and Prevention 
(CDC) issued guidance on the use of PrEP in 2012 and published updated Clinical 
Practice Guidelines on 2014 (CDC, 2014). The major area covered by the guidelines 
are (Table 1 in appendices): 
• Daily oral PrEP has been shown to be effective in reducing the risk of HIV 
acquisition in adults. 
• Current data on the efficacy and safety of PrEP for adolescents are not 
sufficient.  
• HIV infection must be excluded by symptom history and HIV testing 
immediately before PrEP is prescribed. 
• HIV infection should be assessed at least every 3 months and renal function 
at every 6 months after the patients is taking PrEP. 
• Health care provider should provide access, directly or by facilitated referral to 
confirmed effective risk-reduction services.  
 
In July 2015, the White House released an updated National HIV/AIDS Strategy 
for the United States, which highlights PrEP as a main tool in preventing HIV (The White 
House, 2015). In 2012, World Health Organization (WHO) endorsed the use of PrEP to 
MSM, sero-discordant couples, and transgender people (World Health Organization, 
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2012). Based on the findings of recent evidence of effectiveness of PrEP, in 2015 WHO 
broadened and developed the consolidated HIV guidelines to all groups of population 
incorporating MSM, IDUs, sex workers, transgender people, prisoners and other closed 
settings who are at substantial risk of acquiring HIV infection (WHO, 2015). Offering  
PrEP based on individual assessment rather than risk group is key factor in new 
recommendations. New recommendations also focuses on PrEP to be given as an 
additional prevention choice for people who are at substantial risk of HIV infection as 
part of combination HIV prevention approaches (WHO, 2015). Thus, the new 
recommendations facilitate a broader group of risk populations being positioned to 
benefit from this additional prevention alternative. 
 
Key Evidences 
Cost-effectiveness 
A number of studies have evaluated the cost–effectiveness of oral antiretroviral PrEP, 
reporting results as the cost per infection averted, cost per life-year saved, cost per 
quality-adjusted life-year gained, cost per disability-adjusted life-year (DALY) averted 
and years on PrEP per infection averted (Hankins, 2014; WHO, 2015). A recent 
systematic review of 13 of the cost–effectiveness studies for PrEP found that PrEP 
could be a potentially cost-effective addition to HIV-prevention programs, particularly 
when those at highest risk of HIV exposure are prioritized, that is, where HIV incidence 
is highest. However, when the current price of drugs is high, as in Peru, PrEP may not 
be reasonable even if it could have a significant impact among MSM (Gomez et al., 
2013). Studies have found PrEP to be cost-effective - depending on the cost of the drug 
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and delivery systems - when PrEP uptake is higher among people at substantial risk 
(Grant et al., 2014). The results vary widely depending on epidemic type, location and 
model parameters, including efficacy, cost, HIV incidence and target population (Alistar, 
Grant, & Bendavid, 2014; WHO, 2015). For example, while PrEP could have impact in 
key populations such as MSM, the first priority for PWIDs might be expanding access to 
antiretroviral treatment (ART) and opioid substitution therapy. In considering trade-offs, 
prioritizing PrEP for young women in southern Africa who are at alarmingly high risk of 
HIV acquisition can be cost-effective, especially when there are costly obstacles to 
recruiting HIV-positive people for treatment using the same drug (Hankins, Macklin, & 
Warren, 2015). 
 
Equity and Acceptability 
Averting HIV infection among PrEP users will contribute to equitable health 
outcomes by sustaining their health and the health of their sexual partners. Extending 
PrEP recommendations beyond narrowly defined groups (such as MSM and sero-
discordant couples) allows for more equitable access and will reduce future treatment 
costs overall by preventing HIV infection in populations with a high incidence. PrEP 
acceptability has been reported in multiple populations: women, sero-discordant 
couples, female sex workers (FSWs), young women, PWID, transgender people, 
service providers and MSM (Ayala et al., 2013; Brooks et al., 2012; Ferrer et al., 2016; 
Frankis, Young, Lorimer, Davis, & Flowers, 2016; Galea et al., 2011b; Hosek et al., 
2013; Jayakumaran, Aaron, Gracely, Schriver, & Szep, 2016; Mensch, Van Der Straten, 
& Katzen, 2012; Underhill et al., 2012; Van der Elst, Mbogua, Operario, Mutua, Kuo, 
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Mugo, Kanungi, Singh, Haberer, & Priddy, 2013; Yang et al., 2013). Population support 
for the provision of PrEP was based on the knowledge of safety and effectiveness and 
the compatibility of PrEP with other prevention strategies (WHO, 2015). 
 
Feasibility 
Large scale PrEP trials focused on various population groups have proven 
feasibility and safety in terms of administration among diverse trial settings and 
demonstration projects (Baeten et al., 2012; Grant et al., 2014; Grohskopf et al., 2013; 
Hosek et al., 2013; Marrazzo et al., 2015; Martin, Vanichseni, et al., 2014; Mayer et al., 
2015; Peterson et al., 2007; Rajchgot et al., 2016; Thigpen et al., 2012; Van Damme  et 
al., 2012). For example, the iPrEx OLE project and the Partners Demonstration project 
both showed that PrEP implementation is feasible for different populations, including 
men and women (Baeten et al., 2012; Choopanya et al., 2013). The PROUD study, 
conducted in the United Kingdom and designed to mimic real-life settings, demonstrated 
that PrEP is feasible and effective and is not associated with significant changes in 
behavioral risk (McCormack & Dunn, 2015). Similarly, PrEP trials in Botswana, South 
Africa, Thailand and the United States confirmed that protective levels of adherence are 
feasible for most PrEP users (Bekker et al., 2015; Henderson et al., 2015; Holtz et al., 
2015; Liu, Cohen, Vittinghoff, & Anderson, 2015; Mannheimer, Hirsch-Moverman, & 
Loquere, 2015), although challenges remain to achieve optimal PrEP adherence, 
particularly among young people (Liu et al., 2015). Two placebo-controlled trials among 
women found significant barriers to uptake and adherence (Marrazzo et al., 2015; Van 
Damme  et al., 2012). PrEP adherence among women has been high when open-label 
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PrEP is provided (HPTN 067 ADAPT Study and the TDF2 Open Label Extension) 
(Bekker et al., 2015; Thigpen et al., 2012). 
 
Adherence to PrEP 
Studies to date on daily oral PrEP indicate that medication adherence is the key 
to achieving the maximum prevention benefit from HIV acquisition (Baeten et al., 2012; 
Grant et al., 2014; Grohskopf et al., 2013; Marrazzo et al., 2015; Martin, Vanichseni, et 
al., 2014; Peterson et al., 2007; Thigpen et al., 2012; Van Damme  et al., 2012). A 
recent review of the ART adherence studies over the past decade and adherence data 
from completed PrEP trials suggests various approaches to effectively support 
medication adherence (Koenig, Lyles, & Smith, 2013). These approaches include 
educating patients about their medications; helping them anticipate and manage side 
effects; helping them establish dosing routines that aligns with their work and social 
schedules; providing reminder systems and tools; addressing financial, substance 
abuse, or mental health needs that may impede adherence; and facilitating social 
support (Amico, Mansoor, Corneli, Torjesen, & Van Der Straten, 2013; CDC, 2014; 
Koenig, Lyles, & Smith; Tangmunkongvorakul et al., 2013; Ware et al., 2012).  
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METHOD 
 
Participants 
Between June and July 2016, a convenience sample of 400 participants was 
recruited at Connecticut’s largest MMP. Screening eligibility included: i) being 18 years 
or older, ii) reporting HIV-uninfected, iii) reporting drug- or sex-related HIV risk 
behaviors in the past 6 months, and iv) being able to understand, speak, and read 
English. All patients were stabilized on methadone to treat opioid dependence. Among 
the 438 MMP clients approached, 28 did not meet eligibility criteria and an additional 10 
either did not agree to study participation or chose not to complete the entire survey, 
leaving 400 individuals for the final analytical sample. 
 
Study Setting and Procedures 
We conducted a cross-sectional study of high-risk PWUD at Connecticut’s 
largest addiction treatment program (APT Foundation, New Haven, Connecticut), which 
provides opioid agonist treatments (methadone and buprenorphine) and clinical care to 
over 7,000 opioid-dependent PWUD. Convenience sampling was used to recruit 
participants through flyers, peers, word-of-mouth, and direct referral from counselors. 
Screening was conducted by trained research assistants in a private room at APT 
Foundation or by phone. Individuals who met inclusion criteria and expressed interest in 
participating completed informed consent procedures in person and were administered 
a 45-minute survey (range: 40 - 60 minutes) using an audio computer-assisted self-
interview (ACASI). All participants were reimbursed for the time and effort needed to 
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participate in the survey. The study protocol was approved by the Institutional Review 
Board at the University of Connecticut and received board approval from the APT 
Foundation, Inc. 
 
Measures 
In addition to demographic and social characteristics, we assessed health 
insurance status, visits to health care providers in the past 12 months and current 
methadone dose. We assessed whether participants were prescribed any medication 
(other than methadone) in the past 30 days and, for those who were, we assessed 
medication adherence using a self-reported, validated three-item scale developed by 
Wilson et al. (2016). Summary scales were calculated as the mean of the three 
individual items with higher score indicating better adherence (0 – 100) (Wilson, Lee, 
Michaud, Fowler, & Rogers, 2016).  
 
Awareness and Willingness to Use PrEP 
Participants were asked about their awareness and previous use of PrEP. Their 
willingness to use PrEP was assessed after providing a brief description of PrEP 
(Appendix). Participants were asked to respond to a statement “I would be interested in 
taking PrEP to reduce my current risk of HIV infection” on a five-point Likert scale. Their 
score was further dichotomized as “Yes” (strongly agree and agree) and “No” (strongly 
disagree, disagree, and neutral). Some further hypothetical questions were asked to 
assess participants’ anticipation of engaging in HIV risk reduction behaviors while on 
PrEP: “How confident are you that you would always use condoms while on PrEP?”, 
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and “How confident are you that you would stop sharing needles or works completely 
while on PrEP?” The 5-point Likert response ranged from “Not at all confident” to 
“Completely confident”. This variable was further dichotomized as “Yes” (completely 
confident) and “No” (any other response, including being “not at all confident” to “very 
confident”, but “not completely confident”). We chose to dichotomize these variables of 
interest for better interpretability and simplicity and in order to be more conservative in 
operationalizing the variables (i.e., consistently using condom and never sharing of 
injection equipment). 
 
 
Correlates of Willingness to Use PrEP 
Covariate measures included were based on prior research (refs here**). 
Neurocognitive impairment (NCI) was measured using the Brief Inventory of 
Neurocognitive Impairment (BINI), which is a brief, 54-item self-reported measure of 
neuropsychological symptoms (Copenhaver, Shrestha, Wickersham, Weikum, & Altice, 
2016). The overall BINI score, which was obtained by summing responses to all items, 
was converted to standardized scores (i.e., z-scores). Participants with a  z-score ≥ 0.5 
were classified as moderately to severely neurocognitively “impaired”, whereas those 
with a z-score < 0.5 were classified as “not impaired” (Dwan, Ownsworth, Chambers, 
Walker, & Shum, 2015). The overall internal consistency (Cronbach’s alpha) for the BINI 
scale was 0.97. Depressive symptoms were assessed using the 20-item Center for 
Epidemiological Studies Depression Scale (CES-D), with ≥16 indicative of moderate to 
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severe depression (Radloff, 1977). The overall internal consistency (Cronbach’s alpha) 
for the scale was 0.92. 
Alcohol use disorders were measured using the validated 10-item Alcohol Use 
Disorders Identification Test (AUDIT), with standard cut-offs ≥ 8 for men and ≥ 4 for 
women suggestive of an AUD (Babor, Higgins-Biddle, Saunders, & Monteiro, 2001). 
The overall international consistency for the AUDIT was 0.92. Current drug- and sex-
related risk was assessed for the past 30 days using an adapted version of the HIV risk-
taking behavior scale (HRBS) (Ward, Darke, & Hall, 1990). Risk perception for HIV was 
measured by the question “What do you think your current risk of getting HIV is?” with 
possible options being “no risk as all”, “moderate risk”, or “high risk”. Participants’ 
satisfaction with previous HIV prevention methods was assessed using the question 
“Are you satisfied with your current method of HIV protection (e.g., condom use, clean 
needle use)?” 
 
Conjoint Analysis 
We used full-profile conjoint analysis approach to assess the acceptability of 
various hypothetical PrEP-related scenarios and to quantify the importance of key 
hypothetical and known PrEP attributes on acceptability. Briefly, conjoint analysis is a 
statistical technique often used to quantify consumer preferences for goods and 
services. It enables researchers to test what combination of program attributes is most 
critical in participants’ decision-making and which attributes are most preferred (Bridges, 
2003; Ryan et al., 2001). It has been applied successfully to measure preferences in 
economics and market research (Annunziata & Vecchio, 2013; Foxall, Menon, & 
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Sigurdsson, 2016; Uchida, Onozaka, Morita, & Managi, 2014) and recently has gained 
popularity in the health care studies (Bridges, Kinter, Kidane, Heinzen, & McCormick, 
2008; Flynn, 2010; Kievit, Van Hulst, Van Riel, & Fraenkel, 2010; Lee, Newman, 
Comulada, Cunningham, & Duan, 2012; Marshall, McGregor, & Currie, 2010).  
Based on themes that emerged from prior studies on PrEP acceptability 
(Eisingerich et al., 2012; Galea et al., 2011a; Shrestha, Altice, Karki, & Copenhaver, 
2017; Wheelock et al., 2013) and input from PrEP experts, we composed six two-level 
PrEP program design attributes that included: Cost (insurance covered vs. out-of-
pocket), dosing (daily vs. on demand), efficacy level at preventing HIV (95% vs. 75%), 
side-effects (none vs. nausea/dizziness), treatment setting (HIV clinic vs. drug treatment 
clinic), and frequency of HIV testing needed (every 6 months vs. every 3 months) (Table 
2). 
A full-factorial design for six attributes, each with two levels, yielded 64 (26 = 64) 
different PrEP program scenarios. Since asking participants to rate all 64 scenarios 
would be difficult and burdensome, we used a fractional factorial orthogonal design 
(Ryan, McIntosh, & Shackley, 1998) to generate a subset of all of the possible 
combinations called an orthogonal array that allowed estimation of the part-worth 
utilities for all main effects. Part-worth utility is the value respondents attach to a specific 
level of a particular attribute. Relative importance reflects the influence of each attribute 
on a participant’s decision-making. The ‘Generate Orthogonal Design procedure’ was 
used to generate an orthogonal array and is typically the starting point of a conjoint 
analysis. It is commonly used to reduce the number of profiles that have to be 
evaluated, while ensuring enough data are available for statistical analysis, resulting in 
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a carefully controlled set of "profiles" for the respondent to consider (Ryan et al., 1998). 
This resulted in an orthogonal main effects design, thus yielding as much statistical 
information as possible for estimating unbiased, precise preference parameters, such 
as ensuring the absence of multicollinearity between attributes (i.e. attributes included in 
the model are not correlated), equal preference weights in calculating efficiency. The 
statistical procedure involved removing from the original set of 64, scenarios that were 
linearly related to one other. We reduced the number of scenarios from 64 to 8 while 
ensuring that all of the attribute/level combinations appeared with the same frequency.  
The attributes were described in lay language with examples to aid 
comprehension. Participants were then asked to rank the eight hypothetical PrEP 
program scenarios (Figure 1) from 1 (“most likely to use”) to 8 (“least likely to use”), 
which were presented concurrently, but none of the scenarios could share the same 
value. The scenarios were presented in random order to prevent potential biases 
related to order effects. 
 
Data Analyses 
All data analyses were performed using SPSS v. 23 (IBM Corp., 2015), and 
statistical significance was set at p<0.05.  
 
Awareness and Willingness to Use PrEP 
We computed descriptive statistics, including frequencies and percentages for 
categorical variables, and means and standard deviations for continuous variables. 
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Correlates of Willingness to Use PrEP 
After conducting bivariate analyses for significant associations of participants’ 
characteristics with their willingness to use PrEP, we conducted multivariate logistic 
regression analyses on bivariate associations found to be significant at p<0.10. We 
examined the correlates expressed as adjusted odds ratios (aORs) and their 95% 
confidence intervals (95% CI). The final model was ultimately selected based on 
goodness-of-fit using the Hosmer and Lemeshow Test (Hosmer, Hosmer, Le Cessie, & 
Lemeshow, 1997). 
 
Conjoint Analysis 
We used conjoint analysis to assess the acceptability of hypothetical PrEP 
scenarios and to quantify the impact of various PrEP attributes on acceptability. For the 
first conjoint analysis exercise, the acceptability of each of the eight hypothetical PrEP 
program scenarios was derived by averaging individual PrEP program acceptability 
ratings across respondents. Ratings from each PrEP program was transformed into a 
0–100 scale, whereby ‘‘highly likely would accept’’ = 100 and ‘‘highly unlikely would 
accept’’ = 0. For the second conjoint analysis exercise, we used the “conjoint” 
procedure that utilizes the rankings of the different PrEP program scenarios for each 
participant to assess the impact of PrEP attributes. The conjoint procedure uses a set of 
linear regressions to generate utility scores for each attribute level. The utility score, 
called a part worth, is an estimate of the overall preference of utility associated with 
each attribute level used to define the PrEP program. The utility score for each factor 
level is analogous to regression coefficients and provide a quantitative measure of the 
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preference for each factor level, with larger values corresponding to greater preference. 
The relative importance score for each PrEP attribute provides a measure of how 
important the attribute is to overall preference with greater score playing a more 
significant role than those with smaller score. We expressed the utility scores on a 
common scale in percentage terms. We then calculated the relative importance score 
by taking the range of utility scores for any attribute levels (highest minus lowest), 
dividing this by the sum of all the utility ranges, and multiplying by 100 (IBM Corp., 
2015; Ross, Avery, & Foss, 2003). 
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RESULTS 
 
Participant Characteristics 
Among the 400 participants, the average age of the participants was 40.9 ± 11.1 
years and 58.5% were male. Self-reported HIV risk behaviors were highly prevalent with 
57.5% reporting recent drug injection (past 30 days) with two-thirds of these reporting 
sharing needles/works. Of those who were sexually active (82.0%), 39.9% reported 
having multiple sexual partners, yet 85.1% reported condom less sex with casual sexual 
partners. Most participants reported having taken prescribed medication (other than 
methadone) in the past 30 days, with a mean medication adherence score of 73.3 
(SD=15.4) on a scale of 0–100. Approximately one-third of participants were classified 
as being neurocognitively impaired, and 74.3% and 47.0% met screening criteria for 
depression and AUDs, respectively. Self-reported HIV risk behaviors were highly 
prevalent. Over half of participants reported being satisfied with their current method of 
HIV prevention and two-thirds perceived that they were at risk of acquiring HIV.  
 
Awareness and Willingness to Use PrEP 
Only 18% of participants reported having heard of PrEP as a method to prevent 
HIV transmission and 1.8% had ever used it. Conversations with friends (6.5%) and 
health care providers (4.8%) were noted as the top sources of PrEP knowledge (Figure 
1). Nearly two-thirds of participants (62.7%) reported that they would be willing to use 
PrEP to reduce their risk of HIV infection. Participants willing to initiate PrEP were asked 
about their anticipated sexual and drug-related risk behaviors while on PrEP, and only 
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12.5% indicated that they would consistently use condoms while on PrEP. Regarding 
drug-related risk, only 28.2% of participants reported that they would not share injection 
equipment while on PrEP (Figure 1).  
 
Correlates of Willingness to Use PrEP 
While Table 2 shows the bivariate correlates of being willing to initiate PrEP, 
Table 3 shows the independent correlates associated with this outcome in multivariate 
modeling. Specifically, being neurocognitively impaired was associated with over a 
three-fold odds (aOR=3.184, p=0.004) of being willing to initiate PrEP. Additionally, 
compared to those who did not perceive themselves to be at risk for HIV, those with 
moderate (aOR=4.439, p<0.001) and high (aOR=8.044, p<0.001) perceived risk were 
significantly more likely to be willing to initiate PrEP. 
 
Conjoint Analysis 
PrEP acceptability ranged from 30.6% to 86.3% with a mean acceptability of 
56.2% across the eight hypothetical PrEP program scenarios (Table 4). The PrEP 
program scenario with the highest acceptability (scenario 1) had the following attributes: 
lower cost (insurance covered), daily dosing, 95% effective, no side effects, prescription 
at a HIV clinic, and HIV testing every 6 months.  
When the eight PrEP attributes were examined individually, however, the 
marginal utility for each attribute differed from the optimal program on several key 
attributes when comparing the preferred versus the non-preferred attributes. The cost 
associated with PrEP was the single most important attribute for participants. 
  
24 
 
Participants reported higher acceptability if the cost of PrEP was covered by insurance 
(Marginal utility score: MUS=1.43), compared to paying out-of-pocket (MUS = -1.43), 
yielding a net relative importance score (RIS) of 38.8. Efficacy of PrEP had the second-
greatest impact on PrEP acceptability. Participants reported higher acceptability for 
PrEP when it was 95% effective (MUS=0.70) compared with 75% effective (MUS = -
0.70), yielding a RIS of 20.5. Side effects had the third-greatest impact on PrEP 
acceptability with an overall RIS of 11.9. There was a notable preference for PrEP with 
no side effects (MUS = 0.29) compared to PrEP with even minor side effects (MUS = -
0.29). Dosing frequency (RIS = 10.3), treatment location (RIS = 9.9), and frequency of 
associated HIV testing (RIS = 8.3) had relatively low influence on PrEP acceptability. 
Compared to taking PrEP on demand (MUS = -0.03), participants preferred taking PrEP 
on a daily basis (MUS = 0.03). Receiving PrEP in drug treatment clinics (MUS = 0.19) 
rather than in HIV clinics (MUS = -0.19) was preferred. The preferred frequency of 
associated HIV testing was every 6 months (MUS = 0.02) as opposed to every 3 
months (MUS = -0.02) (Table 5 and Figure 3). 
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DISCUSSION 
 
Given the dearth of literature examining the interest in or initiation of PrEP among 
PWUD, we sought to directly assess this risk group for their willingness to use PrEP and 
their perceptions about how PrEP might affect their drug and sexual risk behaviors. 
Furthermore, we aimed to assess PrEP acceptability, as well as utilizing conjoint 
analysis to quantify key attributes associated with PrEP acceptability in this key 
population. Overall, several important findings were gleaned from this study that have 
major implications for PrEP scale-up in MMP settings, where PrEP use among PWUD 
was originally examined (Choopanya et al., 2013).  
Almost none of our participants (<2%) had ever taken PrEP and few (18%) were 
even aware of PrEP. This is especially concerning given that this is a population at high-
risk for HIV, and who have frequent contact with various treatment providers (e.g., 
through MMPs and elsewhere). This represents missed opportunities to initiate, or at 
least discuss, PrEP among PWUD. Limited PrEP awareness and use among PWUD 
here is similar to that reported elsewhere among female sex workers in China (Peng et 
al., 2012) and among other studies of PWUD in the U.S. (Kuo et al., 2016; Stein et al., 
2014), but PrEP awareness here was lower than that reported in studies of MSM (Ferrer 
et al., 2016; Goedel et al., 2016; Hoagland et al., 2016; Young et al., 2013). The higher 
level of knowledge about PrEP in MSM may stem from a number of PrEP initiatives that 
have primarily focused on MSM and HIV sero-negative partners in sero-discordant 
couples (Ware et al., 2012). Recent studies have also shown that many addiction 
treatment providers, with whom MMP patients are in daily contact, have limited 
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awareness of PrEP (Shrestha, Karki, Frederick, & Copenhaver, 2016; Spector, Remien, 
& Tross, 2015). In the context of clinical settings, including MMP patients in this study, 
treatment providers have great potential to engage their at-risk clients about PrEP 
through counseling, referrals, research trials, and may also effectively promote 
adherence to PrEP through counseling and monitoring. Our findings highlight the need 
for ongoing training for MMP providers, so they can refer clients to PrEP and promote 
PrEP adherence, as they would for other services (e.g., offer risk reduction items, HIV 
testing, referral) relevant to HIV prevention.  
When information deficits about PrEP were corrected by describing its potential 
benefits, interest in initiating PrEP increased markedly, with nearly two-thirds (62.7%) of 
participants being willing to initiate PrEP. Importantly, those who stand to benefit the 
most from PrEP (i.e., those at highest risk for HIV) tended to be most interested in it. 
Specifically, those who accurately perceived themselves as being at higher risk for 
acquiring HIV were most willing to initiate it, as well as those with neurocognitive 
impairment, which is associated with higher HIV risk behaviors (Anand, Springer, 
Copenhaver, & Altice, 2010; Huedo-Medina, Shrestha, & Copenhaver, 2016; Shrestha 
& Copenhaver, 2016a). Together, these findings support PrEP expansion for PWUD 
enrolled in MMP.   
The combination of high sex- and drug-related risk in MMP patients suggests that 
PrEP would be ideal for this risk group, just as reported in the original PrEP trial among 
PWID. In addition to the biomedical prevention benefits of PrEP, the structured nature of 
MMPs and the requirement for regular counseling suggests that MMP settings could 
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readily support the integration of PrEP into existing evidenced-based behavioral risk 
reduction strategies. 
Furthermore, we found that higher willingness to initiate PrEP was associated 
with participants having NCI, which is highly prevalent (~30%) among this risk group 
(Shrestha, Huedo-Medina, Altice, Krishnan, & Copenhaver, 2016). In prior studies 
(Anderson, Higgins, Ownby, & Waldrop-Valverde, 2015; Attonito, Devieux, Lerner, 
Hospital, & Rosenberg, 2014; Becker, Thames, Woo, Castellon, & Hinkin, 2011), 
cognitive deficits have been associated with risky behaviors, poor medication 
adherence, and treatment disengagement (Anand et al., 2010; Shrestha, Huedo-
Medina, & Copenhaver, 2015; Verdejo-Garcia & Perez-Garcia, 2007; Vo, Schacht, 
Mintzer, & Fishman, 2014). Given the relationship between NCI and higher HIV risk 
behaviors, this is an important group of PWUD who might benefit from PrEP. NCI may 
also undermine the efficacy of PrEP since high levels of adherence are required for its 
efficacy (Baeten  et al., 2012; Choopanya et al., 2013; Grant et al., 2010; Shrestha, 
Karki, Huedo-Medina, & Copenhaver, 2016; Thigpen  et al., 2012; Van Damme  et al., 
2012). For PWUD with NCI initiating PrEP, it is therefore crucial to couple PrEP with a 
behavioral approach to support medication adherence, such as cues and reminders or 
other cognitive remediation strategies (Barlati, Deste, De Peri, Ariu, & Vita, 2013; Cole-
Lewis & Kershaw, 2010; Finitsis, Pellowski, & Johnson, 2014; Pop-Eleches et al., 2011).  
Participants’ overall perception of HIV risk was relatively high in this cohort of 
PWUD. We found that individuals who perceived themselves to be at higher risk of 
contracting HIV reported greater willingness to initiate PrEP, which is consistent with 
that reported in prior studies among MSM (Eisingerich et al., 2012; Golub, Gamarel, 
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Rendina, Surace, & Lelutiu-Weinberger, 2013; Wheelock et al., 2013; Young et al., 
2013). The results suggest that participants are making rational judgments about their 
own risk levels when considering whether to initiate PrEP. This may indicate not only be 
a concern about risk of HIV infection but also a self-management response to their HIV 
risk behaviors (Young et al., 2013). Thus, self-management programs, which have been 
shown to have positive outcomes in a variety of long-term conditions (e.g., diabetes, 
hypertension, arthritis) (Martin, Chinnock, et al., 2014), may be of specific usefulness to 
promote self-management aspects of HIV prevention, such as HIV risk reduction 
strategies and PrEP. Alternatively, PrEP may be  seen as an important HIV prevention 
approach in itself if, as our data suggest found, these individuals are unlikely to start 
using condoms more consistently (Holt et al., 2012). Overall, our findings suggest the 
need to consider how at-risk PWUD perceive and respond to their HIV risks as this may 
have a significant impact on the development and roll-out of PrEP-related programs 
targeting various risk populations. 
Similar to other PrEP studies, findings here suggest that those who start PrEP 
are unlikely to then modify their risk behaviors. While these data do not support risk 
compensation as an anticipated behavioral response by PWUD, they do suggest that 
this population is ideal for PrEP and opens opportunities for integrating biomedical and 
behavioral interventions to enhance adherence and reduce other sexually transmitted 
infections (STIs) and blood-borne viral infections. Despite variable findings from other 
PrEP studies showing no risk compensation in clinical trials (Grant et al., 2010; 
McCormack et al.; Molina et al., 2015) but elevated risk-taking in other observational 
studies (Golub et al., 2013; Zhou et al., 2012), such responses should be closely 
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examined in further PrEP studies in PWUD. Furthermore, prior studies have shown that 
biomedical approaches to HIV prevention are optimized when they are combined with 
evidence-based behavioral strategies including structural interventions that increase 
access to services, decrease costs, and reduce stigma and discrimination to ensure 
broad scale implementation, teaching HIV risk reduction and PrEP adherence skills, 
routinely testing for HIV and STIs, and monitoring/supporting PrEP adherence over 
time.     
Results from our conjoint analysis reveal variations in participants’ attitudes and 
preferences of PrEP attributes that collectively or individually may help to strengthen the 
PrEP cascade (Liu et al., 2012). PrEP acceptability exceeded 80% for two case 
scenarios. Two key attributes were central to both scenarios – low cost and high (95%) 
efficacy – with other attributes varying between the two scenarios. It is not surprising 
that low cost (PrEP covered by insurance) dominated the individual program attributes, 
especially given the high unemployment level and 78% of the sample earning markedly 
below the poverty level for Connecticut. This finding also aligns with that from previous 
studies which identified cost as one of the major barriers to PrEP acceptability among 
MSM, female sex workers, and male-to-female transgendered individuals (Brooks et al., 
2011; Galea et al., 2011a; Gersh et al., 2014; Schneider et al., 2010; Smith, Toledo, 
Smith, Adams, & Rothenberg, 2012). It is encouraging, however, that most private and 
public insurance plans in the U.S. cover the cost of PrEP, but this may be threatened if 
the Affordable Care Act is repealed, potentially leaving over 20 million people without 
insurance.    
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Efficacy was the second most important attribute, with 95% efficacy, as 
expected, being the preferred alternative, corroborating findings in Peru, a middle-
income setting where patients must pay for their own medications (Galea et al., 2011a). 
In addition, prior studies reported similar findings, where MSM were willing to use PrEP 
with higher efficacy in preventing HIV (Golub, Kowalczyk, Weinberger, & Parsons, 2010; 
Mustanski, Johnson, Garofalo, Ryan, & Birkett, 2013); no such studies exist for PWUD. 
Notable here is while PrEP efficacy exceeds 90% in patients with high adherence, 
efficacy falls markedly at lower adherence levels (Baeten  et al., 2012; Choopanya et 
al., 2013; Grant et al., 2010; Thigpen  et al., 2012). While numerous factors contribute to 
medication adherence (Fisher, Amico, Fisher, & Harman, 2008), mean adherence for 
other medications in this sample was relatively low (Mean = 73.3). Prior research in this 
population suggests a high level of neurocognitive impairment (NCI) (Shrestha & 
Copenhaver, 2016b; Shrestha, Huedo-Medina, et al., 2016; Shrestha et al., 2015; 
Shrestha, Karki, Huedo-Medina, & Copenhaver, 2017), which has been associated with 
risky behaviors, poor medication adherence, and treatment disengagement (Anand et 
al., 2010; Huedo-Medina et al., 2016; Shrestha et al., 2015; Verdejo-Garcia & Perez-
Garcia, 2007; Vo et al., 2014). Thus, NCI may undermine the effectiveness of PrEP if 
prescribed to cognitively impaired individuals, since high levels of adherence to PrEPis 
correlated with its efficacy (Baeten  et al., 2012; Choopanya et al., 2013; Grant et al., 
2010; Shrestha, Karki, Huedo-Medina, et al., 2016; Thigpen  et al., 2012; Van Damme  
et al., 2012). One consideration for scaling up PrEP in PWUD would be to test and 
introduce empirically-based strategies that simultaneously address NCI and medication 
adherence to ensure higher PrEP efficacy. Alternatively, many more PrEP medications 
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are being developed and tested, including injectable, long-acting medications that can 
be administered once every 8-12 weeks (Landovitz, Kofron, & McCauley, 2016; 
Markowitz et al., 2016). In the absence of such data about adherence to PrEP 
medication and concomitant NCI, it may be beneficial to implement a combination HIV 
prevention package that includes evidence-based HIV risk reduction and PrEP 
adherence skills, routinely testing for HIV and STIs, and monitoring/ supporting PrEP 
adherence over time. 
Experiencing side effects like nausea and dizziness had the third greatest impact 
on PrEP acceptability in the conjoint analysis. Not surprisingly, participants were 
concerned about potential side effects from PrEP, opting for scenarios without them. 
Previous studies have shown that potential side effects from PrEP medications as being 
one of the major barriers to uptake (Galea et al., 2011a; Gersh et al., 2014; Mack, 
Odhiambo, Wong, & Agot, 2014; Mustanski et al., 2013), yet numerous studies suggest 
that currently approved PrEP medications have few to no side effects (Baeten  et al., 
2012; Choopanya et al., 2013; Grant et al., 2010; Thigpen  et al., 2012; Van Damme  et 
al., 2012). Strategies like informed or shared decision-making can be useful to help 
guide patients to incorporate their preferences alongside evidence-based information in 
their decisions about initiating a medication like PrEP (Elwyn et al., 2012; Elwyn, 
Frosch, & Kobrin, 2016). To date, such decision aids are unavailable to at-risk 
individuals and pre-PrEP counseling could provide clients with skills, strategies, and 
support for minimizing adverse effects associated with taking PrEP (Van der Elst, 
Mbogua, Operario, Mutua, Kuo, Mugo, Kanungi, Singh, Haberer, Priddy, et al., 2013). 
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Low-threshold PrEP programs, however, may not have the luxury of extensive 
counseling sessions, favoring brief, evidence-based decision aids. 
Participants preferred to receive treatment at an addiction treatment program 
(e.g., MMP) rather than a HIV clinic. Though not explored here, this finding may either 
represent a convenience factor for patients who might prefer integrated or co-located 
services (Sylla, Bruce, Kamarulzaman, & Altice, 2007), or alternatively, they perceived 
high levels of HIV stigma by attending such sites, even though they do not have HIV. 
For patients who preferred this attribute, there may be multiple advantages, including 
either combining supervised of methadone and PrEP medication, which has been 
successfully done for other diseases (Batki, Gruber, Bradley, Bradley, & Delucchi, 2002; 
Bruce et al., 2012; Litwin et al., 2009; Morozova, Dvoryak, & Altice, 2013; O'Connor et 
al., 1999), or when not feasible, to take advantage of the regular interaction with clinical 
staff supervising methadone administration to inquire about adherence and provide brief 
counseling when needed. Although HIV and TB services have been successfully 
integrated into addiction treatment settings (Bachireddy et al., 2014; Haddad, Zelenev, 
& Altice, 2013), further research is needed to ascertain the feasibility of integrating PrEP 
into such settings.  
Consistent with national recommendations, participants in this study preferred 
PrEP to be taken on a daily basis, regardless of event-level risk-taking that would 
support PrEP taken on-demand only as needed. On-demand PrEP has only been 
documented to be effective in reducing HIV transmission only in MSM. Daily PrEP, 
however, is efficacious among all key populations (Baeten  et al., 2012; Choopanya et 
al., 2013; Grant et al., 2010; Thigpen  et al., 2012; Van Damme  et al., 2012). This 
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finding aligns well with their interest in receiving PrEP at addiction treatment settings, 
like MMPs, where there is the potential for integration of services and daily supervision. 
Though integrating HIV testing at addiction treatment settings is an evidence-based 
practice (Metsch et al., 2012), many real-world treatment settings do not integrate such 
practices, preferring to refer offsite for either logistical or staffing reasons (Chadwick, 
Andrade, Altice, & Petry, 2014). Last, our sample generally preferred minimal testing 
and low levels of interaction with their healthcare provider. The desired frequency of HIV 
testing while on PrEP was every six months in this sample, similar to previous studies 
(Eisingerich et al., 2012; Wheelock et al., 2013), but inconsistent with national 
guidelines that recommend side-effect monitoring and testing for HIV and sexually 
transmitted infections every three months (CDC, 2014; WHO, 2015). Where guidelines 
are discordant with patient preferences, however, uptake or retention may be 
suboptimal, especially in PWUD who are presently uninformed about PrEP. In tailoring 
programs for this population, designing better PrEP program with brief follow-up calls or 
texting strategies may address their concerns about more frequently monitoring.  
Our data further indicated that participants were willing to make trade-offs in 
exchange for having the PrEP program they prefer. For example, participants were 
willing to attend a HIV clinic or accept PrEP with lower efficacy to avoid side effects (i.e., 
nausea, dizziness) associated with PrEP. In other instances, participants were willing to 
pay out-of-pocket in exchange for a 20% increase in PrEP efficacy from 75% to 95%. 
Much has been learned from PrEP demonstration programs targeting MSM (Cohen et 
al., 2015; Hosek et al., 2017; Liu et al., 2014; Liu, Cohen, Vittinghoff, & et al., 2016), and 
many such lessons might be applied to PWUD, but nonetheless, the PrEP cascade will 
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be optimized, including satisfaction, if patient preferences are incorporated into 
treatment decision-making process.  
 
Study Limitations 
Our overall findings are not without limitations. As with all cross-sectional studies, 
we are only able to assess associations between variables rather than causal 
relationships. The use of self-reported measures may have resulted in participant 
underreporting of socially undesirable behaviors (e.g., drug- and sex-related risk 
behaviors) or inconsistently reporting (e.g., HIV status) because of stigma or fear of 
judgment. Additionally, our use of self-report measures may have resulted in participant 
underreporting or inconsistent reporting (e.g., HIV status) of socially undesirable 
behaviors. Although a brief explanation about PrEP was provided, we do not know the 
extent to which participants understood every attribute/aspect of PrEP (e.g., 
effectiveness, cost, side-effects, dispensing venue, adherence, etc.) when ranking the 
PrEP program scenarios and/or providing responses regarding their willingness to 
initiate PrEP. The participants in this study were high-risk PWUD enrolled in MMP; thus, 
our findings may not be generalizable to PWUD in other settings. PrEP characteristics 
modelled in our analysis did not include factors such as perception of HIV risk, trust in 
health care providers, stigma and discrimination, or satisfaction with current HIV 
prevention methods, which could also impact PrEP acceptability. We dichotomized our 
variables of interest (e.g., willingness to use PrEP), which may have resulted in the loss 
of some valuable information during the process. Finally, the use of the BINI, although a 
very user-friendly and convenient screening instrument for difficult-to-reach populations, 
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is not designed to measure as many cognitive domains as a comprehensive battery of 
tests.  
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SUMMARY AND FUTURE IMPLICATIONS 
  
PrEP represents an important biomedical innovation in evidence-based primary 
HIV prevention among key risk populations. Although PWUD are one of the key risk 
populations who could benefit from the use of PrEP (CDC, 2014; Shrestha, Karki, Altice, 
et al., 2017; WHO, 2015), there have been no published studies conducted 
incorporating the use of PrEP into HIV prevention approaches targeting this 
underserved group. As part of our formative work, we conducted this study to 
understand whether high-risk PWUD are interested in taking PrEP and how these 
individuals value various aspects of PrEP treatment. As such, this study investigated the 
acceptability of PrEP based on a number of known PrEP attributes and factors related 
to willingness to use PrEP among high-risk PWUD in an addiction treatment setting. To 
our knowledge, this is also the first study to utilize conjoint analysis procedure to 
examine the preferences and future acceptability of attributes of PrEP program among 
high-risk PWUD in the context of a substance abuse treatment setting. Key findings 
include low knowledge about PrEP, but when informed, high levels of PrEP acceptability 
if PrEP delivery programs for PWUD are optimally designed. Findings further suggest 
that PWUD who would benefit from PrEP most were those most interested in receiving 
it. Moreover, the structured setting of MMPs provides an ideal clinical context in which 
to integrate biomedical and behavioral interventions in order to optimize HIV prevention 
efforts. The findings from this study provide preliminary evidence in support of the 
development and implementation of a PrEP program integrated into existing evidence-
based HIV prevention efforts that target high risk PWUD. This will help guide 
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implementation of PrEP among high-risk PWUD in the context of common drug 
treatment settings and has the potential to significantly improve the PrEP continuum of 
care. Future studies are warranted to investigate the actual uptake of PrEP and to 
implement evidence-based interventions to improve PrEP continuum of care among this 
underserved population. 
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Table 1: Characteristics of the participants (N = 400) 
Variable Frequency % 
Age: Mean (±SD) 40.9 (11.1)  
Gender   
 Male 234 58.5 
 Female 166 41.5 
Sexual orientation   
 Heterosexual or straight 345 86.3 
 Homosexual, gay, or lesbian 16 4.0 
 Bisexual 39 9.7 
Ethnicity   
 White 253 63.2 
 African American 70 17.5 
 Hispanic or Latino 61 15.3 
 Other 16 4.0 
Marital status   
 Married 83 20.8 
 Divorced 111 27.8 
 Widowed 14 3.5 
 Single 192 48.0 
High school graduate 293 73.3 
Employed 69 17.3 
Annual Income  
 < $10,000 312 78.0 
 $10,000 - $19,999 57 14.2 
 ≥ $20,000 31 7.8 
Injected drugs (past 30 days) 230 57.5 
Shared needles/works (past 30 days) n = 230  
 No 80 34.8 
 Yes 150 65.2 
Sexually active (past 30 days) 328 82.0 
Number of sexual partners (past 30 days) n = 328  
 1 197 60.0 
 2 – 5 116 35.4 
 ≥ 6 15 4.6 
Always used condom with casual partner n = 328  
 No casual partner 64 19.5 
 No 215 65.6 
 Yes 49 14.9 
Taking prescribed medication 308 77.0 
Medication adherence: Mean (SD) 73.3 (15.4)  
Heard about PrEP 72 18.0 
Ever taken PrEP 7 1.8 
 
Legend: SD: standard deviation; PrEP: pre-exposure prophylaxis
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Table 2: Characteristics of participants and HIV transmission risk behaviors, stratified by 
their willingness to use PrEP 
Variables 
Willingness to use 
OR (95% CI) 
p No 
(n = 149) 
Yes 
(n = 251) 
Characteristics of participants     
Age: Mean (SD) 39.7 (11.4) 41.8 (10.8) 1.017 (.999, 1.037) 0.070 
Gender     
 Male 94 (23.5) 140 (35.0) - - 
 Female 55 (13.8) 111 (27.8) 1.355 (.894, 2.053) 0.152 
Sexual orientation     
 Heterosexual or straight 137 (34.3) 208 (52.0) - - 
 Homosexual, gay, or lesbian 5 (1.3) 11 (2.8) 1.449 (.493, 4.262) 0.500 
 Bisexual 7 (1.8) 32 (8.0) 3.011 (1.292, 7.015) 0.011 
Ethnicity     
 Non-white 44 (11.0) 103 (25.8) - - 
 White 105 (26.3) 148 (37.0) .602 (.391, .928) 0.022 
Marital status     
 Married 32 (8.0) 51 (12.8) - - 
 Divorced 33 (8.3) 78 (19.5) 1.483 (.813, 2.705) 0.199 
 Widowed 4 (1.0) 10 (2.5) 1.569 (.454, 5.426) 0.477 
 Single 80 (20.0) 112 (28.0) .878 (.519, 1.488) 0.630 
High school graduate     
 No 32 (8.0) 75 (18.8) - - 
 Yes 117 (29.3) 176 (44.0) .642 (.399, 1.032)  0.067 
Employed     
 No 277 (69.3) 54 (13.5) - - 
 Yes 51 (12.8) 18 (4.5) 1.054 (.615, 1.807) 0.848 
Income level     
 < $10,000 254 (63.5) 58 (14.5) - - 
 $10,000 - $19,999 52 (13.0) 5 (1.3) .727 (.410, 1.288) 0.274 
 ≥ $20,000 22 (5.5) 9 (2.3) 1.032 (.478, 2.232) 0.935 
Currently have health insurance     
 No 15 (3.8) 4 (1.0) - - 
 Yes 313 (78.3) 68 (17.0) .768 (.286, 2.066) 0.601 
Visited healthcare provider (past 12 months)     
 No 29 (7.2) 5 (1.3) - - 
 Yes 299 (74.8) 67 (16.8) 1.198 (.586, 2.449) 0.621 
Homeless (past 12 months)     
 No 172 (43.0) 26 (6.5) - - 
 Yes 156 (39.0) 46 (11.5) 1.252 (.834, 1.879) 0.278 
Methadone dose: Mean (SD), mg 81.3 (29.9) 81.3 (27.4) 1.000 (.993, 1.007) 0.982 
Taking medication (past 30 days)     
 No 38 (9.5) 54 (13.5) - - 
 Yes 111 (27.8) 197 (49.3) 1.249 (.776, 2.010) 0.360 
Medication adherence: Mean (SD) 75.4 (15.8) 72.2 (15.2) .986 (.970, 1.002) 0.076 
Ever heard of PrEP     
 No 120 (30.0) 208 (52.0) - - 
 Yes 29 (7.2) 43 (10.8) .855 (.508, 1.441)  0.558 
Neurocognitive impairment     
 No 122 (30.5) 157 (39.3) - - 
 Yes 27 (6.8) 94 (23.5) 2.705 (1.659, 4.411) <0.001 
Moderate to Severe Depression     
 No 48 (12.0) 55 (13.8) - - 
 Yes 101 (25.3) 196 (49.0) 1.694 (1.074, 2.671) 0.023 
Alcohol use disorders     
 No 87 (21.8) 125 (31.3) - - 
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 Yes 62 (15.5) 126 (31.5) 1.437 (.940, 2.129) 0.097 
HIV transmission risk behaviors     
During the past 30 days…     
Injected drugs      
 No 72 (18.0) 98 (24.5) - - 
 Yes 77 (19.3) 153 (38.3) 1.460 (.969, 2.198) 0.070 
Shared injection equipment     
 No 32 (13.9) 48 (20.9) - - 
 Yes 45 (19.6) 105 (45.7) 1.556 (.882, 2.744) 0.127 
Had sex     
 No 28 (7.0) 44 (11.0) - - 
 Yes 121 (30.3) 207 (51.7) 1.089 (.645, 1.839) 0.751 
Number of sexual partners     
 1 83 (25.3) 114 (34.8) - - 
 2 – 5 35 (10.7) 81 (24.7) 1.685 (1.035, 2.742) 0.036 
 ≥ 6 3 (0.9) 12 (3.7) 2.912 (.797, 10.647) 0.106 
Always used condom with regular partner     
 No 105 (34.1) 177 (57.5) - - 
 Yes 8 (2.6) 18 (5.8) 1.335 (.561, 3.177) 0.514 
Always used condom with casual partner     
 No 80 (30.3) 135 (51.1) - - 
 Yes 12 (4.5) 37 (14.0) 1.827 (.901, 3.707) 0.095 
Diagnosed with STIs (past 12 months)     
 No 128 (32.0) 218 (54.5) - - 
 Yes 21 (5.3) 33 (8.3) .923 (.512, 1.663) 0.789 
Perceived risk for HIV infection     
 No risk at all 65 (16.3) 64 (16.0) - - 
 Moderate 57 (14.2) 88 (22.0) 1.568 (.970, 2.533) 0.065 
 High 27 (6.8) 99 (24.8) 3.724 (2.153, 6.441) <0.001 
Satisfied with current method of HIV prevention     
 No 56 (14.0) 106 (26.5) - - 
 Yes 93 (23.3) 145 (36.3) .824 (.544, 1.248) 0.360 
 
Legend: PrEP: Pre-exposure prophylaxis; SD: Standard deviation; OD: Odds ratio; STIs: Sexually transmitted 
infections; OR: Odds ratio 
Note: STIs in the past 12 months 
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Table 3: Multivariate logistic regression models of factors associated with willingness to 
use PrEP 
Variables 
Willingness to use PrEP 
aOR 95% CI P 
Age 1.017 .986, 1.049 0.280 
Sexual orientation    
 Heterosexual or straight - - - 
 Homosexual, gay, or lesbian 1.378 .279, 6.814 0.694 
 Bisexual 2.920 .930, 9.171 0.067 
Ethnicity    
 Non-white - - - 
 White 1.188 .566, 2.496 0.648 
High school graduate    
 No - - - 
 Yes 1.040 .482, 2.240 0.920 
Neurocognitive impairment    
 No - - - 
 Yes 3.184 1.459, 6.949 0.004 
Moderate to Severe Depression    
 No - - - 
 Yes 1.219 .535, 2.779 0.638 
Alcohol use disorders    
 No - - - 
 Yes 1.023 .526, 1.986 0.948 
Injected drugs    
 No - - - 
 Yes .986 .483, 2.012 0.968 
Number of sexual partners    
 1 - - - 
 2 – 5 .714 .350, 1.455 0.353 
 ≥ 6 .629 .126, 3.139 0.572 
Always used condom with casual partner    
 No - - - 
 Yes 3.401 .940, 6.307 0.062 
Perceived risk for getting HIV     
 No risk at all - - - 
 Moderate 4.439 1.959, 7.060 <0.001 
 High 8.044 3.012, 13.481 <0.001 
Hosmer and Lemeshow Test: Chi-square = 5.439; p = 0.710 
 
Legend: aOR: Adjusted odds ratio  
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Table 4: Acceptability (Mean) of hypothetical pre-exposure prophylaxis (PrEP) scenarios with different attributes in order 
of decreasing acceptability among participants 
PrEP 
Scenarios 
PrEP Acceptability 
Mean 
PrEP Attributes 
Cost Dose Efficacy Side Effects Treatment Location HIV Testing Needed 
1 86.28 Insurance covered Daily use 95% None HIV clinic Every 6 months 
2 82.09 Insurance covered On demand 95% Nausea/Dizziness Drug treatment clinic Every 3 months 
3 70.75 Insurance covered Daily use 75% None Drug treatment clinic Every 3 months 
4 57.25 Insurance covered On demand 75% Nausea/Dizziness HIV clinic Every 6 months 
5 51.44 Out of Pocket On demand 95% None Drug treatment clinic Every 6 months 
6 39.84 Out of Pocket Daily use 95% Nausea/Dizziness HIV Clinic Every 3 months 
7 31.63 Out of Pocket On demand 75% None HIV clinic Every 3 months 
8 30.56 Out of Pocket Daily use 75% Nausea/Dizziness Drug treatment clinic Every 6 months 
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Table 5: Relative importance and marginal utilities of PrEP attribute levels among 
participants 
Attributes Attribute Levels 
Relative Importance 
Score (%) 
Cost 
Insurance Covered 
38.8 
Out of pocket 
Efficacy 
95% 
20.5 
75% 
Side-effects 
None 11.9 
Nausea/dizziness  
Dosing 
Daily use 
10.3 
On demand 
Treatment location 
Drug treatment clinic 
9.9 
HIV clinic 
HIV testing needed 
Every 6 months 
8.3 
Every 3 months 
 
Legend: PrEP: pre-exposure prophylaxis, RIS: relative importance score
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Figure 1: Variables of interest related to PrEP among participants (N = 400) 
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Figure 2: Example of full-profile conjoint task (hypothetical PrEP program scenarios) 
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Figure 3: Marginal utilities of pre-exposure prophylaxis (PrEP) attributes’ levels among participants 
 
 
Legend: PrEP: pre-exposure prophylaxis 
* Constant: 4.467 (0.110) 
Pearson’s R: 0.998 
Kendall’s tau: 1.000
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Table 1: Summary of Guidance for PrEP Use 
 Men Who Have Sex with Men 
Heterosexual Men and 
Women 
Injection Drug Users 
Detecting 
Substantial Risk 
of Acquiring HIV 
Infection 
• HIV-positive sexual 
partner 
• Recent bacterial STI 
• Multiple sexual partners 
• History of inconsistent 
or no condom use 
• Commercial sex work 
• HIV-positive sexual 
partner 
• Recent bacterial STI 
• Multiple sexual partners 
• History of inconsistent 
or no condom use 
• Commercial sex work 
• High-prevalence area  
• HIV-positive injecting 
partner 
• Sharing needles and 
works 
• Recent drug treatment 
(but currently injecting) 
Clinically 
Eligible 
• Documented negative HIV test result before prescribing PrEP  
• No signs/symptoms of acute HIV infection 
• Normal renal function; no contraindicated medications 
• Documented hepatitis B virus infection and vaccination status 
Prescription Daily, continuing, oral doses of TDF/FTC (Truvada), ≤90-day supply 
Other Services 
Follow-up visits at least every 3 months to provide: 
• HIV test, medication adherence counseling, behavioral risk reduction support. 
• Side effect assessment, STI symptom assessment 
• At 3 months and every 6 months thereafter, assess renal function 
• Every 6 months, test for bacterial STIs 
• Do oral/rectal STI 
testing 
• Assess pregnancy 
intent 
• Pregnancy test every 3 
months 
• Access to clean 
needles/syringes and 
drug treatment services 
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Table 2: Outcomes from Various PrEP RCTs 
Study & Population 
Protective Effect 
All Study Participants 
Protective Effect 
Participants with Higher Adherence 
Heterosexual men and women (Partners PrEP; TDF-2 
study): Botswana, Kenya and Uganda 
62% - 76% Up to 90% 
Gay men and other MSM (iPrEX study): Brazil, Ecuador, 
Peru, South Africa, 
Thailand and the United States 
44% 90% 
People who inject drugs (Bangkok Tenofovir Study) 49% 75% 
FEM-PrEP: heterosexual women in Kenya, South Africa 
and the United Republic of Tanzania 
<30% adherence, no effect <30% adherence, no effect 
VOICE heterosexual women in South Africa, Uganda and 
Zimbabwe 
<30% adherence, no effect <30% adherence, no effect 
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Brief description of pre-exposure prophylaxis (PrEP) provided to the participants 
“There is a new way to prevent HIV infection for people who may be exposed to the 
virus. It is called Pre-Exposure Prophylaxis or PrEP. It involves an HIV-negative person 
taking a pill daily, on an ongoing basis (starting before an exposure and continuing after 
for as long as the person is at risk) to reduce their risk of HIV infection. Research 
suggests that PrEP is generally safe and is highly effective (over 90%) in preventing 
HIV infection if taken every day. It is much less effective if not taken every day and does 
not protect against other sexually transmitted infections. Taking PrEP would require a 
visit to a doctor every three months in order to be tested for HIV, STIs and side effects.” 
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Flyer 
University of Connecticut 
 
Volunteers Wanted for a Research Study 
 
Improving health care services during drug treatment 
 
We are conducting a research study to assess what people think of Pre-Exposure Prophylaxis 
(PrEP) and how familiar people are with various kinds of communication technologies (i.e., landline 
phone, cell phone, and internet) and what tools would be the most helpful while in treatment to keep 
track of medical appointments or help remember to take medications. Upon meeting criteria, you will 
have to complete a survey that will take approximately 40-45 minutes. 
 
You may be eligible to participate if ALL of the following apply to you: 
• You are 18 years or older 
• You are HIV-negative 
• You are enrolled in methadone maintenance program 
• You are available to participate in a survey 
• You are able to understand, speak, and read English.  
 
Participants will receive reimbursement for $25 for completing the survey. 
 
To learn more about this research, please contact:  
Brian, Jen, or Roman (Phone #: (203)-781-4690) 
 
This research is conducted under the direction of Dr. Michael Copenhaver, Department of Allied 
Health Sciences, University of Connecticut. 
 
UConn Protocol # H16-116 
 
 
 
 
 
 
 
 
R
e
s
e
a
rc
h
 S
tu
d
y
 
U
C
o
n
n
 P
ro
to
c
o
l #
 H
1
6
-0
9
0
 
C
o
n
ta
c
t B
ria
n
, J
e
n
, o
r R
o
m
a
n
 
P
h
o
n
e
 #
: 2
0
3
-7
8
1
-4
6
9
0
 
 
 R
e
s
e
a
rc
h
 S
tu
d
y
 
U
C
o
n
n
 P
ro
to
c
o
l #
 H
1
6
-0
9
0
 
C
o
n
ta
c
t B
ria
n
, J
e
n
, o
r R
o
m
a
n
 
P
h
o
n
e
 #
: 2
0
3
-7
8
1
-4
6
9
0
 
 
 R
e
s
e
a
rc
h
 S
tu
d
y
 
U
C
o
n
n
 P
ro
to
c
o
l #
 H
1
6
-0
9
0
 
C
o
n
ta
c
t B
ria
n
, J
e
n
, o
r R
o
m
a
n
 
P
h
o
n
e
 #
: 2
0
3
-7
8
1
-4
6
9
0
 
 
 R
e
s
e
a
rc
h
 S
tu
d
y
 
U
C
o
n
n
 P
ro
to
c
o
l #
 H
1
6
-0
9
0
 
C
o
n
ta
c
t B
ria
n
, J
e
n
, o
r R
o
m
a
n
 
P
h
o
n
e
 #
: 2
0
3
-7
8
1
-4
6
9
0
 
 
 R
e
s
e
a
rc
h
 S
tu
d
y
 
U
C
o
n
n
 P
ro
to
c
o
l #
 H
1
6
-0
9
0
 
C
o
n
ta
c
t B
ria
n
, J
e
n
, o
r R
o
m
a
n
 
P
h
o
n
e
 #
: 2
0
3
-7
8
1
-4
6
9
0
 
 
 R
e
s
e
a
rc
h
 S
tu
d
y
 
U
C
o
n
n
 P
ro
to
c
o
l #
 H
1
6
-0
9
0
 
C
o
n
ta
c
t B
ria
n
, J
e
n
, o
r R
o
m
a
n
 
P
h
o
n
e
 #
: 2
0
3
-7
8
1
-4
6
9
0
 
 
 
 77 
 
Informed Consent 
 
Consent Form for Participation in a Research Study 
 
 
 
Principal Investigator: Dr. Michael Copenhaver 
Student Researcher: Roman Shrestha 
Study Title: HIV prevention and PrEP adherence among high-risk drug users 
Sponsor: National Institute on Drug Abuse 
 
Introduction 
First of all, thank you for taking the time to look over this invitation to participate in our study. You 
are invited to participate in a research study designed to provide us with information to improve our 
HIV prevention services. We are interested in hearing how familiar you are with a new treatment, 
Pre-exposure Prophylaxis (PrEP), and whether you believe that PrEP would be helpful as part of 
HIV prevention series while you are in drug treatment. We are also interested in hearing your 
opinion about the kinds of communication technologies (i.e., landline phone, cell phone, and 
internet) that you think may be helpful for you to use to support your health care while you are in 
drug treatment (e.g., medical appointment reminders). You have been asked to participate 
because you are HIV-negative and currently enrolled in drug treatment at the APT Foundation.   
 
In order to decide whether or not you want to be a part of this study, you should know enough 
about its risks and benefits to make an informed decision. This consent form gives you detailed 
information about the study, which a member of the research team will discuss with you. This 
discussion should go over all aspects of this research:  its purpose, the procedures that will be 
performed, any risks of the procedures, and potential benefits. We also encourage you to ask 
questions now and at any time. Once you understand the study, you will be asked if you wish to 
participate; if so, you will be asked to sign this consent form, and you will be given a copy. 
 
Why is this study being done? 
The purpose of this research study is to hear your opinion about some ways to improve our HIV 
prevention services. We want to know how helpful you think the use of pre-exposure 
prophylaxis (PrEP) would be as part of HIV prevention in drug treatment, how familiar you are 
with various kinds of communication technologies (i.e., landline phone, cell phone, and internet), 
and what tools would be the most helpful while you’re in drug treatment to keep track of when 
you have medical appointments or need to take medications.  
 
What are the study procedures?  What will I be asked to do? 
If you agree to take part in this study, you will be asked to participate in a survey that ask you to 
answer questions about your knowledge and suggestions about PrEP, whether you own and 
use various communication devices (e.g., cell phone, smart phones), your use of the internet, as 
well as questions about memory challenges you may experience that may be improved by using 
communication devices while in drug treatment. The survey will last between 40-45 minutes and 
will be held in a private room at the APT Foundation. 
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What are the risks or inconveniences of the study?   
We believe there are no known risks associated with this research study; however, a possible 
inconvenience may be the time it takes to complete the study and the possibility of experiencing 
discomfort regarding questions related to drug use and sexual risk behaviors in the survey. You 
are free not to answer such questions and also to withdraw yourself from participating in the 
research process at any time you like to do so.  
 
If you would like to talk to a counselor about your feelings at any time, we can connect you with 
a counselor at the APT Foundation. 
 
What are the benefits of the study? 
You may not directly benefit from this research; however, we hope that your participation in the 
study may assist researchers to understand whether it will one day be helpful for care providers 
to develop PrEP programs and use communication technology (e.g., cell phone, smartphone) to 
help you remember things like when to take medications, come to medical appointments, and to 
get more out of your health care.  
 
Will I receive payment for participation?  Are there costs to participate? 
Your participation is purely voluntary. There are no costs and you will be paid $25 in cash after 
the completion of the survey. 
 
How will my personal information be protected? 
We will make every effort to insure your privacy and confidentiality. If you do not choose to 
participate in this study, all information that you have given us will be destroyed immediately. If you 
do choose to participate, in all of our study records, you will be identified by a number and your 
name will be known only to the researcher. Your name will not appear in any publication or be 
released to anyone without your written consent. You should understand, however, that there is a 
risk that you will be recognized by other patients or staff involved in the study and that you may be 
recognized as a participant in a research program. But this is no greater than the usual risk of 
identification that occurs in your clinical care. 
  
The following procedures will be used to protect the confidentiality of your data.  The researchers 
will keep all study records (including any codes to your data) locked in a secure location.   
Research records will be labeled with a code.  The code will be derived from a number (e.g. 
“sequential 3 digit code) that reflects how many people have enrolled in the study.  A master key 
that links names and codes will be maintained in a separate and secure location.  The master key 
will be destroyed after 3 years after the completion of this study. All electronic files (e.g., database, 
spreadsheet, etc.) containing identifiable information will be password protected.  Any computer 
hosting such files will also have password protection to prevent access by unauthorized users.  
Only the members of the research staff will have access to the passwords.  Data that will be 
shared with others will be coded as described above to help protect your identity.  At the conclusion 
of this study, the researchers may publish their findings.  Information will be presented in summary 
format and you will not be identified in any publications or presentations. 
 
Data that we collect from you may be shared with other researchers in the future, but only after 
your name and all identifying information have been removed. 
 
We will do our best to protect the confidentiality of the information we gather from you but we 
cannot guarantee 100% confidentiality. Your confidentiality cannot be guaranteed if your record is 
subpoenaed in a court of law or in the event the researcher determines that you are a clear and 
imminent danger to yourself and/or others. In addition, confidentiality cannot be guaranteed if you 
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disclose that you are intending to or currently sexually or physically abusing a child or an elderly 
person. 
 
You should also know that the UConn Institutional Review Board (IRB) and Research Compliance 
Services may inspect study records as part of its auditing program, but these reviews will only 
focus on the researchers and not on your responses or involvement.  The IRB is a group of people 
who review research studies to protect the rights and welfare of research participants. 
 
Can I stop being in the study and what are my rights? 
You do not have to be in this study if you do not want to.  If you agree to be in the study, but later 
change your mind, you may drop out at any time.  There are no penalties or consequences of any 
kind if you decide that you do not want to participate. You do not have to answer any question that 
you do not want to answer. 
 
Whom do I contact if I have questions about the study? 
Take as long as you like before you make a decision. We will be happy to answer any question you 
have about this study. If you have further questions about this study or if you have a research-
related problem, you may contact the principal investigator, Dr. Michael Copenhaver at (860) 
486-2846 or the student researcher, Roman Shrestha at (203) 781-4690. If you have any 
questions concerning your rights as a research participant, you may contact the University of 
Connecticut Institutional Review Board (IRB) at 860-486-8802. 
 
Documentation of Consent: 
I have read this form and decided that I will participate in the project described above.  Its 
general purposes, the particulars of involvement and possible risks and inconveniences have 
been explained to my satisfaction.  I understand that I can withdraw at any time.  My signature 
also indicates that I have received a copy of this consent form. 
 
 
____________________  ____________________  __________ 
Participant Signature:   Print Name:    Date: 
 
 
____________________  ____________________  __________ 
Signature of Person   Print Name:    Date: 
Obtaining Consent 
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Screening Form 
Screening Questionnaires 
 
Interviewer:  ____________________________    Date:  _________________ 
Client name: ____________________________  Contact:  _________________ 
1. Are you enrolled at the APT Foundation drug treatment program?  Y_______   N ________ 
 If No, where?  ________________________________  
 Dose _________ 
2. Are you a physician, counsellor, or other health care provider working with patients enrolled 
at the APT Foundation? Y____ N ____   
 If No, where?  ________________________________ 
3. Do you currently drink alcohol? ________   (If yes, how much?) _________________ 
4. Do you have children? _______________     (If yes) Do you have custody? _________ 
5. Do you live in New Haven? ______________ (If no, where)? _____________________ 
6. Do you have reliable transportation? _________   
7. Have you ever been tattooed? ___________ 
8. What is the highest level of school that you have completed? _________________  
9. Have you ever been tested for HIV? ________  
What year was the most recent test? _______ 
What was the result of the test? ___________ 
10. Have you seen a psychiatrist in the past 6 months? ____  
 If yes, for what?   Depression ___ PTSD ______ Schizophrenia __________  
    Bipolar_______  Anxiety _____    Other__________________ 
 If other, explain _____________ 
11. Are you currently suicidal or homicidal? ______ 
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Survey Questionnaires 
Demographics 
 
1. Interviewer: ______________________ 
 
2. Research staff, please fill in the participant number. _____ 
 
3. What year were you born? Please enter the four-digit year _____ 
 
4. What is your age? _____ 
 
5. What is your gender? 
a. Male 
b. Female 
c. Transgender 
 
6. What is your sexual orientation? 
a. Heterosexual or straight 
b. Homosexual, gay, queer, or lesbian 
c. Bisexual 
d. Other 
 
7. Which best describes you? 
a. White 
b. African American or Black 
c. Hispanic or Latino 
d. Asian or Pacific Islander 
e. Other 
 
8. What is your current marital status? 
a. Now married or living with partner 
b. Divorced 
c. Separated 
d. Widowed 
e. Never married 
 
9. What is the highest level of education you have completed? 
a. Middle School (Jr. High School) or Less 
b. Some High School, No Diploma 
c. High School Graduate / GED or Equivalent 
d. Junior (2-year) College 
e. Technical / Trade / Vocational School 
f. Some College (4-year college or university) 
g. College Graduate (4-year college or university) 
 
10. What is your primary language? 
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a. English 
b. Spanish 
c. Other 
 
11. What is your employment status? 
a. Working now (this includes full time work, part time work) 
b. Only temporarily laid off, sick leave or maternity leave 
c. Unemployed and looking for work 
d. Retired 
e. Disabled, permanently or temporarily 
f. Keeping house (full-time homemaker) 
g. Student 
h. Unemployed and not looking for work (not disabled or on medication) 
i. Other 
 
12. Which is closest to your current income? 
a. Under $10,000 
b. $10,000 to $19,999 
c. $20,000 to $29,999 
d. $30,000 or more 
 
13. Do you have health insurance? 
1. No 
2. Yes 
 
14. What type of coverage do you have? 
a. Private health insurance 
b. Medicare 
c. Medi-gap 
d. Medicaid 
e. SCHIP 
f. Military healthcare 
g. Indian Health Service 
h. State Sponsored Plan 
i. Other government plan 
j. Single service plan 
k. Alliance 
l. Other coverage 
m. No coverage 
 
15. Have you seen a doctor, nurse, or other health care provider in the past 12 months? 
1. No 
2. Yes 
 
16. In the past 12 months, have you been homeless at any time? By homeless, I mean you 
were living on the street, in shelter, in a single room occupancy hotel, or in a car. 
1. No 
2. Yes 
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17. Are you currently homeless? 
1. No 
2. Yes 
 
18. Are you currently on methadone maintenance program? 
1. No 
2. Yes 
 
19. What is your current methadone dose? _____ 
 
20. What do you often use to help you remember take your medication? 
a. Pillbox 
b. Alarm 
c. Take it at the same time each day 
d. Ask family and friends 
e. Use a pill calendar or drug reminder chart 
f. Leave notes to remind yourself 
g. Email or calendar reminder 
h. Nurse call 
i. Text service 
j. None  
 
Communication Technology and mHealth Scale 
 
I. Access to and Frequency of Use of Communication Technology 
 
1. Do you own or have access to the following devices on a daily basis (check all that apply)? 
 
a. Landline telephone 
b. Cell phone (without internet access) 
c. Cell phone (with internet access, i.e. a Smartphone) 
d. Tablet (e.g., iPad, Samsung Galaxy Tab, Kindle Fire etc.) 
e. Laptop 
f. Personal Computer (PC) 
g. Other devices (please write all other type of communication/mobile devices you own 
or have daily access to; e.g.,Personal Digital Assistant, Google Glass, Samsung 
Smartwatch etc.)  
 
2. On a scale from 1 to 6 (with 1=never, 2=rarely, 3=sometimes, 4=often, 5=all the time, and 
6=do not own), how often do you use the following ? 
 
Note: If yo do not own one of the following devices, select ‘Do not own’; if you own the 
device but do not use it, select ‘Never’.  
 
 1 
Never 
2 
Rarely 
3 
Sometimes 
4 
Often 
5 
All the time 
6 
Do not own 
Landline       
Cell phone       
Smartphone       
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Tablet       
Laptop       
PC       
Other       
 
II. Cell Phone/Smartphone Use 
 
1. How many cell phones (including Smartphones) have you ever owned?  
 
2. How many cell phones (including Smartphones) do you own currently?  
 
3. Given below are different types of activities that cell phones can be used for. On a scale 
from 1 to 5 (with 1=never, 2=rarely, 3=sometimes, 4=often, 5=all the time), please indicate 
how often you engage in the following activities on your cell phone or Smartphone. 
 
Note: If your cell phone does not have a particular feature allowing you to carry out one or 
more of the following activities, select ‘N/A’; however, if your cell phone has the feature but 
you do no use it for that activity, then select ‘Never’. For example, if your cell phone does 
not have internet capability, select N/A for internet-related activities like accessing the 
internet, sending or receiving emails, online banking etc. However, if your cell phone has 
internet capability and you do not use it, then select ‘Never’. 
 
 Never Rarely Sometimes Often All the time N/A 
Make or receive phone calls       
Take a picture       
Record video       
Send or receive text 
messages 
      
Access the internet       
Send or receive emails       
Download applications       
Listen to music       
Watch videos       
Online banking       
Play games       
Online social networking 
(e.g., Facebook, Twitter, 
etc.) 
      
Use health-related apps       
Reading e-books       
 
III. mHealth Acceptance  
 
Mobile technologies such as cell phones can be used in several ways to influence health 
outcomes, such as assessing health markers, reminding patients about medication intake and 
tracking health behaviors. This use of mobile technology in health research is called mHealth. 
 
1. On a scale from 1 to 5 (with 1 being ‘not interested at all’ and 5 being ‘extremely interested’), 
how interested would you be in using mHealth to remind you to take your medication? 
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1 
Not interested  
at all 
2 
Slightly 
interested 
3 
Somewhat 
interested 
4 
Moderately 
interested 
5 
Extremely 
interested 
 
IF ‘NOT INTERESTED AT ALL’, SKIP TO QUESTION 4. 
 
2. How frequently are you interested to receive reminders (via phone calls, text messaes, 
and/or emails) to remind you to take your medication? 
 
Daily Weekly Monthly 
 
3. Which of the following would you prefer the most to receive a reminder to take your 
medication? (choose one) 
 
Phone call Text messages Emails They are all equally fine 
 
4. On a scale from 1 to 5 (with 1 being ‘not interested at all’ and 5 being ‘extremely interested’), 
how interested would you be in using mHealth devices to receive information about HIV? 
 
1 
Not interested  
at all 
2 
 
3 
Somewhat 
interested 
4 5 
Extremely 
interested 
 
IF ‘NOT INTERESTED AT ALL’, SKIP TO QUESTION 7. 
 
5. How frequently are you interested to receive information about HIV using mHealth devices 
(via phone calls, text messaes, and/or emails)? 
 
Daily Weekly Monthly 
 
6. Which of the following would you prefer the most to receive information about HIV (choose 
one): 
 
Phone call Text messages Emails They are all equally fine 
 
7. On a scale from 1 to 5 (with 1 being ‘not interested at all’ and 5 being ‘extremely interested’), 
how interested would you be in using mHealth in assessing your health behaviors? 
 
1 
Not interested  
at all 
2 
 
3 
Somewhat 
interested 
4 5 
Extremely 
interested 
 
IF ‘NOT INTERESTED AT ALL’, SKIP TO SECTION V. 
 
8. On a scale from 1 to 5 (with 1 being ‘not interested at all’ and 5 being ‘extremely interested’), 
how interested would you be in using mHealth in assessing drug use behaviors? 
 
1 
Not interested  
at all 
2 
 
3 
Somewhat 
interested 
4 5 
Extremely 
interested 
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9. On a scale from 1 to 5 (with 1 being ‘not interested at all’ and 5 being ‘extremely interested’), 
how interested would you be in using mHealth in assessing your sexual behaviors? 
 
1 
Not interested  
at all 
2 
 
3 
Somewhat 
interested 
4 5 
Extremely 
interested 
 
 
Brief Inventory of Neurocognitive Impairment (BINI) Scale 
 
Below is a list of problems which some people have. Please read each one carefully, and ask 
yourself how much that statement applies to you, in the past month. 
 
Statements 
0 
Not at all 
1 
Slightly 
2 
Somewhat 
3 
Moderately 
4 
Extremely 
I have trouble concentrating.      
My mind won't stay on any one 
thing. 
     
I have difficulty paying attention.      
My mind tends to wander.      
I often feel restless.      
I am easily distracted.      
I have trouble making up my mind.      
I have difficulty making decisions.      
I forget what I read.      
I feel frustrated quite often.      
My judgment is poor.      
Something is wrong with my mind.’      
I have trouble remembering 
important things. 
     
My thinking becomes blocked.      
I fall apart under pressure.      
I tend to give up easily.      
I forget where I put things.      
I feel everything is an effort.      
I often lose things.      
I get lost easily.      
My mind frequently goes blank.      
My reactions are slow.      
My arithmetic is poor.      
Doing simple math problems in my 
head is difficult. 
     
I count with my fingers.      
I do things slowly.      
My mind is dull.      
I forget the names of common 
things. 
     
I have trouble learning new things.      
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I have forgotten much what learned 
in school. 
     
My words get mixed up.      
I have trouble writing sentences.      
My mind works slowly.      
My hearing has become worse.      
I have trouble following 
conversations. 
     
I have serious memory problems.      
I am forgetful.      
I have trouble remembering 
people’s names. 
     
I have forgotten many things from 
my childhood. 
     
I am very clumsy.      
I drop things frequently.      
I bump into things.      
I fall down sometimes.      
I faint sometimes.      
I have trouble with the left side of 
my body. 
     
Part of my body is paralyzed.      
Part of my body feels numb.      
I have trouble walking.      
I have trouble with the right side of 
my body. 
     
I have a bad temper.      
I have urges to break and smash 
things. 
     
I get into arguments frequently.      
I have trouble sleeping.      
I suffer from severe pain.      
I have severe headaches.      
I have had a head injury.      
I have been knocked unconscious.      
 
Pre-Exposure Prophylaxis (PrEP) 
 
There is a new way to prevent HIV infection for people who may be exposed to the virus. It is 
called Pre-Exposure Prophylaxis or PrEP. The use of anti-HIV medication can keep HIV 
negative people from becoming infected. When taken properly, PrEP is safe and highly effective 
(up to 99%) in preventing HIV infection. The key is taking one pill every day. 
 
1. Before participating in this survey, have you ever heard about PrEP? 
0 
No 
1 
Yes 
   
 
2. Where did you hear about PrEP? Check all that apply. 
a. A friend 
b. A family member 
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c. A healthcare provider 
d. A work colleague 
e. An HIV prevention counselor 
f. On a website 
g. At a community meeting 
h. From a newspaper 
i. Other 
 
3. Have you ever used PrEP? 
0 
No 
1 
Yes 
   
 
IMB Items for PrEP 
 
Information 
 
1. Uninfected individuals who are at high risk of HIV infection (e.g., through unsafe sex or 
needle sharing) should take PrEP. 
0 
False 
1 
True 
   
 
2. PrEP is highly effective for preventing HIV if it is taken on a daily basis. 
0 
False 
1 
True 
   
 
3. Before taking PrEP, people need to be tested to confirm that they are not already 
infected with HIV. 
0 
False 
1 
True 
   
 
4. When on PrEP, I don’t need to use new or clean needles. 
0 
False 
1 
True 
   
 
5. PrEP provides protection against other sexually transmitted infections (STIs), like 
gonorrhea and chlamydia. 
0 
False 
1 
True 
   
 
6. When on PrEP, I don’t need to use condoms. 
0 
False 
1 
True 
   
 
7. I can stop taking PrEP if my risk of getting HIV infection becomes low because of 
changes in my life. 
0 
False 
1 
True 
   
 
8. While I’m on PrEP, I will need to go for regular doctor visits. 
0 
False 
1 
True 
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9. The cost associated with the PrEP medication is not covered by the insurance. 
0 
Strongly 
disagree 
1 
Disagree 
2 
Neither agree 
or disagree 
3 
Agree 
4 
Strongly 
agree 
 
10. PrEP does not provide complete protection against HIV. 
0 
Strongly 
disagree 
1 
Disagree 
2 
Neither agree 
or disagree 
3 
Agree 
4 
Strongly 
agree 
 
11. Taking PrEP means I am putting myself at risk for HIV. 
0 
Strongly 
disagree 
1 
Disagree 
2 
Neither agree 
or disagree 
3 
Agree 
4 
Strongly 
agree 
 
12. The short-term side-effects of PrEP may include nausea and dizziness. 
0 
False 
1 
True 
   
 
Motivation  
1. It is important to me to not to get sexually transmitted infections (STIs), including HIV, in 
the next year. 
0 
Not important 
at all 
1 
Slightly 
important 
2 
Neutral 
3 
Very 
important 
4 
Extremely 
important 
 
2. How satisfied are you with your current method of HIV protection (e.g., condom use, 
clean needle use)? 
0 
Very 
dissatisfied 
1 
Dissatisfied 
2 
Unsure 
3 
Satisfied 
4 
Very 
satisfied 
 
3. If I were on PrEP, I’m sure that PrEP would be effective in protecting me from HIV-
infection 
0 
Strongly 
disagree 
1 
Disagree 
2 
Neither agree 
or disagree 
3 
Agree 
4 
Strongly 
agree 
 
4. I think I would be less worried about HIV infection if I were on PrEP. 
0 
Strongly 
disagree 
1 
Disagree 
2 
Neither agree 
or disagree 
3 
Agree 
4 
Strongly 
agree 
 
5. If I were on PrEP, it would take the worry out of the sex. 
0 
Strongly 
disagree 
1 
Disagree 
2 
Neither agree 
or disagree 
3 
Agree 
4 
Strongly 
agree 
 
6. If I were on PrEP, I would NOT be concerned about the potential side-effects of PrEP. 
0 1 2 3 4 
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Strongly 
disagree 
Disagree Neither agree 
or disagree 
Agree Strongly 
agree 
 
7. I feel uncomfortable being prescribed a new medication. 
0 
Strongly 
disagree 
1 
Disagree 
2 
Neither agree 
or disagree 
3 
Agree 
4 
Strongly 
agree 
 
8. If I were on PrEP, taking it properly as prescribed would be hard. 
0 
Strongly 
disagree 
1 
Disagree 
2 
Neither agree 
or disagree 
3 
Agree 
4 
Strongly 
agree 
 
9. If I were on PrEP, I won’t have to worry about using condoms. 
0 
Strongly 
disagree 
1 
Disagree 
2 
Neither agree 
or disagree 
3 
Agree 
4 
Strongly 
agree 
 
10. If I were on PrEP, I won’t have to worry about sharing needles and works. 
0 
Strongly 
disagree 
1 
Disagree 
2 
Neither agree 
or disagree 
3 
Agree 
4 
Strongly 
agree 
 
11. If I were on PrEP, I won’t have to worry about my partner’s HIV status. 
0 
Strongly 
disagree 
1 
Disagree 
2 
Neither agree 
or disagree 
3 
Agree 
4 
Strongly 
agree 
 
12. I’m not concerned about the cost associated with PrEP medication. 
0 
Strongly 
disagree 
1 
Disagree 
2 
Neither agree 
or disagree 
3 
Agree 
4 
Strongly 
agree 
 
13. I would take PrEP if I know someone (e.g., friend, family member) who is currently taking 
it. 
0 
Strongly 
disagree 
1 
Disagree 
2 
Neither agree 
or disagree 
3 
Agree 
4 
Strongly 
agree 
 
14. I have a responsibility to contribute to HIV prevention efforts by using PrEP. 
0 
Strongly 
disagree 
1 
Disagree 
2 
Neither agree 
or disagree 
3 
Agree 
4 
Strongly 
agree 
 
15. I have family members or friends to encourage me to take PrEP properly. 
0 
Strongly 
disagree 
1 
Disagree 
2 
Neither agree 
or disagree 
3 
Agree 
4 
Strongly 
agree 
 
16. If I disclose that I’m on PrEP to my sex partner, he/she will be comfortable with it. 
0 1 2 3 4 
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Strongly 
disagree 
Disagree Neither agree 
or disagree 
Agree Strongly 
agree 
 
Behavioral Skills 
Questions 
0 
Not at all 
confident 
1 
Somewhat 
confident 
2 
Moderately 
confident 
3 
Very 
confident 
4 
Completely 
confident 
How confident are you that you would 
remember to take PrEP every day? 
     
How confident are you that you would 
stick to your PrEP regimen even if 
you have some side-effects (e.g., 
nausea)? 
     
How confident are you that you could 
make PrEP part of your daily routine? 
     
How confident are you that you could 
get PrEP refills before you run out? 
     
How confident are you that you could 
fill your PrEP prescription no matter 
what it costs? 
     
How confident are you that you could 
continue with your PrEP regimen 
even if getting to your clinic 
appointments is a major hassle? 
     
How confident are you that you would 
use condoms while on PrEP? 
     
How confident are you that you would 
stop sharing needles or works while 
on PrEP? 
     
How confident are you that you could 
continue with your PrEP regimen 
even when people close to you say it 
isn’t a good idea. 
     
How confident are you that you could 
discuss using PrEP with your partner. 
     
How confident are you that you could 
use PrEP even if your partner didn’t 
like it. 
     
 
Intent to use PrEP 
 
1. I would be interested in taking PrEP to reduce my current risk of HIV infection. 
0 
No 
1 
Yes 
   
 
Drug use 
 
The next section will contain some questions about your use of drugs. 
 
1. Have you used any illicit drugs in the pasts 3 months? 
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a. Yes 
b. No 
 
2. In the last 3 months, which illicit drug have you used? 
a. Heroin 
b. Cocaine 
c. OxyContin 
d. Crystal meth 
e. Percocet 
f. Marijuana 
g. others 
 
3. In the last 3 months, what has been your primary method of illicit opiate use? 
a. IV injection 
b. Smoke 
c. Snort 
d. Oral 
e. Non-IV injection 
 
4. In the last 3 months, have you injected any illicit drugs? 
a. Yes 
b. No 
 
The HIV Risk-Taking Behavior Scale (HRBS) 
 
Now, I'm going to ask you a few questions about your drug use for the last month, and, The next 
part of the questionnaire concerns your sex life over the last month. 
 
Questions 0 1 2 3 4 5 
How many times have you hit up (i.e. 
injected any drugs) in the last month? 
Hasn’t 
hit up 
Once 
a 
week 
or less 
More than 
once a week 
(but less than 
once a day) 
Once a 
day 
2-3 
times a 
day 
More 
thaan 3 
times a 
day 
How many times in the last month 
have you used a needle after 
someone else had already used it? 
No 
times 
One 
time 
Two times 3-5 times 6-10 
times 
More 
than 10 
times 
How many different people have used 
a needle before you in the last 
month? 
None  One 
person 
Two people 3-5 
people 
6-10 
people 
More 
than 10 
people 
How many times in the last month 
has someone used a needle after you 
have used it? 
None One 
person 
Two people 3-5 
people 
6-10 
people 
More 
than 10 
people 
How often, in the last month, have 
you cleaned needles before re-using 
them? 
Doesn’t 
re-use 
Every 
time 
Often Sometim
es 
Rarely Never 
Before using needles again, how 
often in the last month did you use 
bleach to clean them? 
Doesn’t 
re-use 
Every 
time 
Often Sometim
es 
Rarely Never 
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How many people, including clients, 
have you had sex with in the last 
month? 
None One 
person 
Two people 3-5 
people 
6-10 
people 
More 
than 10 
people 
How often have you used condoms 
when having sex with your regular 
partner(s) in the last month? 
No 
regular 
partner 
Every 
time 
Often  Sometim
es 
Rarely Never 
How often did you use condoms 
when you had sex with casual 
partners? 
No 
casual 
partners 
Every 
time 
Often Sometim
es 
Rarely Never 
How often have you used condoms 
when you have been paid for sex in 
the last month? 
No paid 
sex 
Every 
time 
Often Sometie
ms 
Rarely Never 
How many times did you have anal 
sex in the last month? 
No 
times 
One 
time 
Two times 3-5 times 6-10 
times 
More 
than 10 
times 
 
 
1. What do you think your current risk of getting HIV is? Please consider your involvement in 
HIV transmission risk behaviors (e.g., needle sharing, no condom use) if applicable. 
a. No risk at all 
b. A little bit of risk 
c. More than a little bit of risk 
d. A lot of risk 
 
2. Have you ever been diagnosed with any sexually transmitted infections (other than HIV) 
in the last 12 months? For example: Chlamydia, gonorrhea, syphilis, herpes, genital 
warts, etc. 
a. Yes 
b. No 
 
Medication Adherence 
 
1. In the last 30 days, haave you taken any medications? 
a. Yes 
b. No 
 
2. In the last 30 days, on how many days did you miss at least one dose of any of the 
medication you are taking? 
 
3. In the last 30 days, how often did you take your medication in the way you were 
supposed to? 
1. Never 
2. Rarely 
3. Sometimes 
4. Usually 
5. Almost always 
6. Excellent 
 
4. In the last 30 days, how good a job did you do at taking your medication in the way you 
were supposed to? 
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1. Very poor 
2. Poor 
3. Fair  
4. Good 
5. Very good 
6. excellent 
 
